DelveInsight’s ‘Diabetic macular edema (DME)- Market Insights, Epidemiology, and Market Forecast—2030’ report delivers an in-depth understanding of the DME , historical and forecasted epidemiology as well as the DME market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.
The DME market report provides current treatment practices, emerging drugs, DME market share of the individual therapies, current and forecasted DME market size from 2018 to 2030 segmented by seven major markets. The Report also covers current DME treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Study Period: 2018–2030
DME Overview
DME is triggered by diabetic retinopathy (DR), a well-known complication of diabetes. DR is the most prevalent diabetic eye disease and the leading cause of irreversible blindness in people in their working years in the developed and other developing countries. DR is caused by long-term damage to the retina’s small blood vessels. The leakage of fluid into the retina may lead to swelling of the surrounding tissue, including the macula. If left untreated, fluid can leak into the macula’s center, called the fovea, the part of the eye where sharp, straight-ahead vision occurs. The fluid makes the macula swell, blurring vision. This condition is called DME. The definition of clinically significant macular edema (CSME) is the most significant outcome of the Early Treatment Diabetic Retinopathy Study (ETDRS); it established a method for classifying and diagnosing DME and determining when treatment is required.
Previously, DME was defined as CSME or not, and focal laser treatment was initiated only for CSME. Then, DME was subcategorized into two main categories: focal diabetic macular edema (fDME) and diffuse diabetic macular edema (dDME).
DME Diagnosis
For the diagnosis of CSME, one of the following characteristics must be present on clinical examination: Any retinal thickening within 500 μm of the center of the macula. Hard exudates within 500 μm of the center of the macula with adjacent retinal thickening. Retinal thickening at least 1 disc area in size, any part of which is within 1 disc diameter of the macula’s center. DME diagnosis is clinically performed by fundoscopy; when the center of the macula (fovea centralis) is thickened or swollen, this is referred to as a clinically significant central-involved macular edema (CI-CSME). It is referred to as a clinically significant non-central-involved macular edema (NCI-CSME) when it is unaffected. Apart from this, tests that help in the diagnosis of DME are visual acuity, refractive error examination, fluorescein angiography (FA), optical coherence tomography (OCT) scan, pupil examination, slit-lamp examination, and retinal examination. However, if the diagnosis is delayed or the condition is left untreated, complications can arise and may even permanently impair the vision.
DME Treatment
Treatment for DME mainly involves the usage of anti-VEGF Drugs, corticosteroids, and Laser photocoagulation. The current standard of care for DME is intravitreal injection. Nonsteroidal anti-inflammatory drugs (NSAIDs), in the form of eye drops, are sometimes used either before or after cataract surgery to prevent the development of macular edema. Currently, intravitreal anti-VEGF agents are the preferred first-line treatment for DME. The three most used anti-VEGF drugs are Avastin (off-label), Eylea, and Lucentis. Corticosteroids are mostly a second-line treatment option. These anti-inflammatory drugs are usually administered via eye drops, pills, or injections of sustained-release corticosteroids into or around the eye. The US FDA approved sustained-release corticosteroid implants for more serious or longer-lasting conditions are Ozurdex, and Iluvien.
Key Findings
In 2020, the overall prevalent cases of DME accessed to be around 1,862,529 in the 7MM, which are expected to grow during the forecast period, i.e., 2021–2030.
The disease epidemiology covered in the report provides historical as well as forecasted DME epidemiology [segmented as Total Prevalent Cases of DME, Total Diagnosed Prevalent cases of DME, Gender-specific Diagnosed Prevalent Cases of DME, Age-specific Diagnosed Prevalent Cases of DME, Subgroups-Specific Diagnosed Prevalent Cases of DME and Treated cases of DME] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2021 to 2030.
Drug chapter segment of the DME report encloses the detailed analysis of DME developmental stage pipeline drugs. It also helps to understand the DME clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
DME Marketed Therapies
Lucentis (Ranibizumab): Genentech/Novartis
Lucentis, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with DME. It binds to the receptor-binding site of active VEGF-A forms, including the biologically active, cleaved form of this molecule, VEGF110. In January 2011, the European Medicines Agency (EMA) approved Lucentis in patients with visual impairment due to DME. Whereas, in August 2012, Lucentis (ranibizumab injection) was approved by the US FDA for treatment of DME. Lucentis was developed by Genentech, a member of the Roche Group. The company retains commercial rights in the US, and Novartis has exclusive commercial rights for the rest of the world. Outside the US, Lucentis is approved in more than 110 countries to treat patients with DME.
Eylea (Aflibercept): Bayer/Regeneron Pharmaceuticals/Santen
Aflibercept is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 formulated as an iso-osmotic solution for intravitreal administration. In July 2014, the US FDA approved Eylea (aflibercept) injection for the treatment of DME. Later on, in the same year Eylea received approval from European Commission followed by Japan’s Ministry of Health, Labour and Welfare (MHLW) to treat DME patients. Eylea solution for injection into the eye has been approved in approximately 100 countries (ex-US) for five different indications for adults. It was co-developed and co-marketed as Eylea by Regeneron and Bayer (also marketed by Santen in Japan).
Note: Full and detailed list of emerging therapies will be provided in the final report.
DME Emerging Drugs
Faricimab (RG 7716): Roche
Faricimab, also known as RG 7716, is the first investigational bispecific antibody designed for the eye with CrossMab technology. It targets two distinct pathways – via angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A) – that drive several retinal conditions. Ang-2 and VEGF-A contribute to vision loss by destabilizing blood vessels, causing new leaky blood vessels to form and increasing inflammation. By simultaneously blocking both pathways involving Ang-2 and VEGF-A, faricimab is designed to stabilize blood vessels, potentially improving vision outcomes for longer for people living with retinal conditions. Three distinct Phase III trials, NCT04432831, NCT03622593, and NCT03622580, are currently ongoing for DME and are anticipated to be completed by 2023, 2023 and 2021, respectively.
Beovu (RTH258; brolucizumab): Novartis
Beovu, formerly known as RTH258, is one of the lead product of Novartis. The drug is the most clinically advanced, humanized single-chain antibody fragment (scFv) in development explicitly designed for the eye. Single-chain antibody fragments are highly sought after in drug development due to properties like small size, enhanced tissue penetration, rapid clearance from systemic circulation, and drug delivery characteristics. In preclinical studies, brolucizumab inhibited activation of VEGF receptors through the prevention of the ligand-receptor interaction.
ADVM-022: Adverum Biotechnologies
ADVM-0022 is an investigational gene therapy being developed by Adverum for the treatment of wet-AMD and DME. It utilizes a propriety vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette. ADVM-022 is administered as a one-time intravitreal injection (IVT), designed to deliver long-term efficacy and reduce the burden of frequent anti-VEGF injections, optimize patient compliance and improve vision outcomes for patients with wet AMD and DME. Adverum is currently evaluating ADVM-022 in the INFINITY Phase II (NCT04418427) trial in patients with DME. This ongoing trial is a multicenter, randomized, double-masked, active comparator-controlled trial designed to assess a single IVT injection of ADVM-022 in patients with DME. The company is looking forward to sharing the data from this trial in the second half of 2021.
THR-149: Oxurion
THR-149, is a plasma kallikrein (PKal) inhibitor for the treatment of DME. Its mechanism of action includes the inhibition of the plasma kallikrein-kinin (PKaI-kinin) system through which THR-149 prevents the induction of retinal vascular permeability, inflammation, and angiogenesis. It has been shown that DME patients have raised levels of PKal and that the vitreous level of PKal varies less compared to VEGF, making it a potentially more effective target for treating DME. Currently, this drug is in Phase II (KALAHARI: NCT04527107) clinical study which is a randomized, prospective, multicenter study assessing multiple (3) injections of THR-149 in two parts (part A and part B). The company expected the Part A data by mid-2021 and topline results from Part B are expected in the first half of 2023.
LKA651: Novartis
LKA651, an investigational drug also known as NOV-9, is an erythropoietin inhibitor being developed by Novartis to treat patients with DME. The company is currently conducting Phase II (NCT03927690) randomized, active-controlled, patient and investigator-masked, multiple-dose, proof-of-concept study of intravitreal LKA651 in patients with DME. This study, which estimates to involve 90 patients, is expected to be completed by November 2021.
Note: Full and detailed list of emerging therapies will be provided in the final report.
Key Findings
The DME market size in the 7MM is expected to change during the study period 2018–2030, at a CAGR of 3.2%. In 2020, according to the DelveInsight’s estimates, the highest market size of DME is accessed in the United States followed by Germany, and Japan.
The United States Market Outlook
In United States, the total market size of DME therapies is expected to increase at a CAGR of 5.5% during the study period (2018–2030).
The drugs which are in pipeline include:
1. ADVM-022: Adverum Biotechnologies
2. GB-102: Graybug Vision
3. Faricimab (RG 7716): Roche
4. Beovu (RTH258; brolucizumab): Novartis
5. KVD001: KalVista Pharmaceuticals
6. APX3330: Ocuphire Pharma
7. THR-149: Oxurion
8. YD-312: YD Life Science
9. LKA651: Novartis
10. Abicipar: Allergan (AbbVie)/Molecular Partners
11. Luminate (ALG-1001, Risuteganib): Allergo Opthalmics/ Bausch Health
12. KSI-301: Kodiak Sciences
13. Xipere (CLS-TA): Clearside Biomedical
Note: Detailed emerging therapies assessment will be provided in the final report.
Analysts Insight
At present, market is currently dominated by anti-VEGFs. Secondary findings suggest that about half of the US ophthalmologists still prescribe off-label bevacizumab as first-line DME therapy. The pharmaceutical competitive landscape of DME is quite robust as several companies are involved in the development of emerging novel thrapies. Upcoming drug therapies are based on unique mechanisms which targets distinct pathways. In addition, the patent expiration of both the marketed anti-VEGF drugs in coming years will open huge window of opportunities for the drugs in pipeline. It is projected that the future of DME care is going to trend toward prolonged ocular half-life therapies with less average injections per year, as well as more innovative approaches which possess better safety and efficacy profile. If such therapies at decent price are eventually successfully commercialized, will change the current standard of care for DME patients.
Anti-VEGFs (Eylea and Luentis) are the first line defense treatment for DME but due to their high cost, off label drugs like Avastin (bevacizumab) comes into the picture. Avastin is not approved for DME but it has proved to be beneficial and effective for a large patient population. In order to make Eylea and Luentis more accessible to patients and reimbursing them for financial assistance, there are certain Patient assistance programs (PAPs) which are of great use for the patients. Both the approved anti-VEGFs have specific Co-pay Programs. Apart from this, in France, Eylea and dexamethasone have been reimbursed by the healthcare system since September and October of 2015, respectively, while Ranibizumab has been reimbursed since 2012.
To keep up with current market trends, we take KOLs and SME’s opinion working in the DME domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or DME market trend. This will support the clients in potential upcoming novel treatment by identifying the over DME scenario of the market and the unmet needs.
We perform Competitive and Market Intelligence analysis of the DME Market by using various Competitive Intelligence tools that includes – SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Market Insights:
Epidemiology Insights:
Current Treatment Scenario and Emerging Therapies:
1. Key Insights
2. Report Introduction
3. Diabetic Macular Edema Market Overview at a Glance
3.1. Market Share (%) Distribution of Diabetic Macular Edema in 2018
3.2. Market Share (%) Distribution of Diabetic Macular Edema in 2030
4. Executive Summary of Diabetic Macular Edema
5. Epidemiology and Market Forecast Flow
6. Disease Background and Overview
6.1. Introduction
6.2. Signs and Symptoms
6.3. Causes of DME
6.4. Risk factors of DME
6.5. Classification of DME
6.6. Pathophysiology of DME
6.6.1. Inflammation (Leukostasis, Inflammatory Cytokines)
6.6.2. Protein kinase C (PKC) pathway
6.6.3. Advanced glycation endproducts (AGEs) pathway
6.6.4. Polyol (sorbitol) pathway
6.6.5. Hexosamine pathway
6.6.6. Mechanisms acting on the Blood-retinal Barrier (BRB)
6.6.7. Vascular endothelial growth factor (VEGF)
6.6.8. The effects of the VEGF family
6.6.9. Activation and inhibition of the VEGF pathway
6.6.10. The role of VEGF in the pathophysiology of DME
6.6.11. Cytokines as predictors and mediators of DME
6.7. Diagnosis
6.7.1. Diagnostic Guidelines
7. Current Treatment
7.1. Anti-VEGF Drugs
7.2. Anti-inflammatory treatments
7.3. Laser photocoagulation
7.4. Small molecule
7.5. Treatment Algorithm
7.5.1. International Council of Ophthalmology: ICO Guidelines for Diabetic Eye Care
8. Epidemiology and Patient Population
8.1. Key Findings
8.2. Assumptions and Rationale
8.3. Epidemiology Scenario: 7MM
8.3.1. Total Prevalent Cases of DME in the 7MM
8.3.2. Total Diagnosed Prevalent cases of DME in the 7MM
8.3.3. Gender-specific Diagnosed Prevalent Cases of DME in the 7MM
8.3.4. Age-specific Diagnosed Prevalent Cases of DME in the 7MM
8.3.5. Subgroups-Specific Diagnosed Prevalent Cases of DME in the 7MM
8.3.6. Treated cases of DME in the 7MM
8.4. The United States
8.4.1. Total Prevalent Cases of DME in the United States
8.4.2. Total Diagnosed Prevalent cases of DME in the United States
8.4.3. Gender-specific Diagnosed Prevalent Cases of DME in the United States
8.4.4. Age-specific Diagnosed Prevalent Cases of DME in the United States
8.4.5. Subgroups-Specific Diagnosed Prevalent Cases of DME in the United States
8.4.6. Treated cases of DME in the United States
8.5. EU-5 Epidemiology
8.6. Germany
8.6.1. Total Prevalent Cases of DME in Germany
8.6.2. Total Diagnosed Prevalent cases of DME in Germany
8.6.3. Gender-specific Diagnosed Prevalent Cases of DME in Germany
8.6.4. Age-specific Diagnosed Prevalent Cases of DME in Germany
8.6.5. Subgroups-Specific Diagnosed Prevalent Cases of DME in Germany
8.6.6. Treated cases of DME in Germany
8.7. France
8.7.1. Total Prevalent Cases of DME in France
8.7.2. Total Diagnosed Prevalent cases of DME in France
8.7.3. Gender-specific Diagnosed Prevalent Cases of DME in France
8.7.4. Age-specific Diagnosed Prevalent Cases of DME in France
8.7.5. Subgroups-Specific Diagnosed Prevalent Cases of DME in France
8.7.6. Treated cases of DME in France
8.8. Italy
8.8.1. Total Prevalent Cases of DME in Italy
8.8.2. Total Diagnosed Prevalent cases of DME in Italy
8.8.3. Gender-specific Diagnosed Prevalent Cases of DME in Italy
8.8.4. Age-specific Diagnosed Prevalent Cases of DME in Italy
8.8.5. Subgroups-Specific Diagnosed Prevalent Cases of DME in Italy
8.8.6. Treated cases of DME in Italy
8.9. Spain
8.9.1. Total Prevalent Cases of DME in Spain
8.9.2. Total Diagnosed Prevalent cases of DME in Spain
8.9.3. Gender-specific Diagnosed Prevalent Cases of DME in Spain
8.9.4. Age-specific Diagnosed Prevalent Cases of DME in Spain
8.9.5. Subgroups-Specific Diagnosed Prevalent Cases of DME in Spain
8.9.6. Treated cases of DME in Spain
8.10. The United Kingdom
8.10.1. Total Prevalent Cases of DME in the United Kingdom
8.10.2. Total Diagnosed Prevalent cases of DME in the United Kingdom
8.10.3. Gender-specific Diagnosed Prevalent Cases of DME in the United Kingdom
8.10.4. Age-specific Diagnosed Prevalent Cases of DME in the United Kingdom
8.10.5. Subgroups-Specific Diagnosed Prevalent Cases of DME in the United Kingdom
8.10.6. Treated cases of DME in the United Kingdom
8.11. Japan Epidemiology
8.11.1. Total Prevalent Cases of DME in Japan
8.11.2. Total Diagnosed Prevalent cases of DME in Japan
8.11.3. Gender-specific Diagnosed Prevalent Cases of DME in Japan
8.11.4. Age-specific Diagnosed Prevalent Cases of DME in Japan
8.11.5. Subgroups-Specific Diagnosed Prevalent Cases of DME in Japan
8.11.6. Treated cases of DME in Japan
9. Patient Journey
10. Key Endpoints in Diabetic Macular Edema
11. Marketed Therapies
11.1. Key Cross of Marketed Therapies
11.2. Lucentis (Ranibizumab): Genentech/Novartis
11.2.1. Drug Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trial
11.2.5. Ongoing Current Pipeline Activity
11.3. Eylea (Aflibercept): Bayer/Regeneron Pharmaceuticals/Santen
11.3.1. Drug Description
11.3.2. Regulatory Milestones
11.3.3. Other Developmental Activities
11.3.4. Pivotal Clinical Trial
11.3.5. Ongoing Current Pipeline Activity
12. Emerging Therapies
12.1. Key Cross of Emerging Therapies
12.2. Beovu (RTH258; brolucizumab): Novartis
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.3. Faricimab (RG 7716): Roche
12.3.1. Product Description
12.3.2. Clinical Development
12.3.3. Safety and Efficacy
12.4. KSI-301: Kodiak Sciences
12.4.1. Product Description
12.4.2. Other Developmental Activities
12.4.3. Clinical Development
12.4.4. Safety and Efficacy
12.5. ADVM-022: Adverum Biotechnologies
12.5.1. Product Description
12.5.2. Other Developmental Activities
12.5.3. Clinical Development
12.6. GB-102: Graybug Vision
12.6.1. Product Description
12.6.2. Other Developmental Activities
12.6.3. Clinical Development
12.6.4. Safety and Efficacy
12.7. THR-149: Oxurion
12.7.1. Product Description
12.7.2. Other Developmental Activities
12.7.3. Clinical Development
12.7.4. Safety and Efficacy
12.8. LKA651: Novartis
12.8.1. Product Description
12.8.2. Other Developmental Activities
12.8.3. Clinical Development
12.8.4. Safety and Efficacy
12.9. APX3330: Ocuphire Pharma
12.9.1. Product Description
12.9.2. Other Developmental Activities
12.9.3. Clinical Development
12.10. YD-312: YD Life Science
12.10.1. Product Description
12.10.2. Other Developmental Activities
12.10.3. Clinical Development
12.10.4. Safety and Efficacy
12.11. Abicipar: Allergan (AbbVie)/Molecular Partners
12.11.1. Product Description
12.11.2. Other Developmental Activities
12.11.3. Clinical Development
12.11.4. Safety and Efficacy
12.12. Luminate (ALG-1001, Risuteganib): Allergo Opthalmics/ Bausch Health
12.12.1. Product Description
12.12.2. Other Developmental Activities
12.12.3. Clinical Development
12.12.4. Safety and Efficacy
12.13. Xipere (CLS-TA): Clearside Biomedical
12.13.1. Product Description
12.13.2. Other Developmental Activities
12.13.3. Clinical Development
12.13.4. Safety and Efficacy
12.14. KVD001: KalVista Pharmaceuticals
12.14.1. Product Description
12.14.2. Other Developmental Activities
12.14.3. Clinical Development
12.14.4. Safety and Efficacy
13. Conjoint Analysis of DME Therapies
14. Diabetic Macular Edema: Seven Major Market Analysis
14.1. Key Findings
14.2. Market Outlook
14.3. 7MM Market Size
14.3.1. Total Market Size of DME in the 7MM
14.3.2. Market Size of DME by Treatment Options in the 7MM
14.4. The United States Market Size
14.4.1. Total Market Size of DME in the United States
14.4.2. Market Size of DME by Treatment Options in the United States
14.5. EU-5 Market Size
14.6. Germany
14.6.1. Total Market size of DME in Germany
14.6.2. Market Size of DME by Treatment Options in Germany
14.7. France
14.7.1. Total Market size of DME in France
14.7.2. Market Size of DME by Treatment Options in France
14.8. Italy
14.8.1. Total Market size of DME in Italy
14.8.2. Market Size of DME by Treatment Options in Italy
14.9. Spain
14.9.1. Total Market size of DME in Spain
14.9.2. Market Size of DME by Treatment Options in Spain
14.10. The United Kingdom
14.10.1. Total Market size of DME in the United Kingdom
14.10.2. Market Size of DME by Treatment Options in the United Kingdom
14.11. Japan
14.11.1. Total Market size of DME in Japan
14.11.2. Market Size of DME by Treatment Options in Japan
15. Market Access and Reimbursement
15.1. National Institute for Health and Care Excellence (NICE) Assessment
15.2. Institute for Quality and Efficiency in Health Care (IQWiG) Assessment
15.3. Transparency Committee - Haute Autorité de Santé (HAS) of France
16. Market Drivers
17. Market Barriers
18. SWOT Analysis
19. Unmet Needs
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
List of Table
Table 1: Summary of DME; Market, Epidemiology, and Key Events (2018–2030)
Table 2: Difference between normal and DR affected eye
Table 3: Causes of Macular Edema
Table 4: International Clinical DME Disease Severity Scale
Table 5: Clinically Significant Macular Edema
Table 6: Visual Acuity Test
Table 7: Slit-lamp examination
Table 8: Indirect ophthalmoscopy
Table 9: Laser treatments in DME
Table 10: DME Treatment Potential Side Effects
Table 11: Total Prevalent Cases of DME in the 7MM, In Thousands (2018–2030)
Table 12: Total Diagnosed Prevalent Cases of DME in the 7MM (2018–2030)
Table 13: Gender-specific Diagnosed Prevalent Cases of DME in the 7MM (2018–2030)
Table 14: Age-specific Diagnosed Prevalent Cases of DME in the 7MM (2018–2030)
Table 15: Subgroups-Specific Diagnosed Prevalent Cases of DME in the 7MM (2018–2030)
Table 16: Treated Cases of DME in the 7MM (2018–2030)
Table 17: Total Prevalent Cases of DME in the United States (2018–2030)
Table 18: Total Diagnosed Prevalent Cases of DME in the United States (2018–2030)
Table 19: Gender-specific Diagnosed Prevalent Cases of DME in the United States (2018–2030)
Table 20: Age-specific Diagnosed Prevalent Cases of DME in the United States (2018–2030)
Table 21: Subgroups-Specific Diagnosed Prevalent Cases of DME in the United States (2018–2030)
Table 22: Treated Cases of DME in the United States (2018–2030)
Table 23: Total Prevalent Cases of DME in Germany (2018–2030)
Table 24: Total Diagnosed Prevalent Cases of DME in Germany (2018–2030)
Table 25: Gender-specific Diagnosed Prevalent Cases of DME in Germany (2018–2030)
Table 26: Age-specific Diagnosed Prevalent Cases of DME in Germany (2018–2030)
Table 27: Subgroups-Specific Diagnosed Prevalent Cases of DME in Germany (2018–2030)
Table 28: Treated Cases of DME in Germany (2018–2030)
Table 29: Total Prevalent Cases of DME in France (2018–2030)
Table 30: Total Diagnosed Prevalent Cases of DME in France (2018–2030)
Table 31: Age-specific Diagnosed Prevalent Cases of DME in France (2018–2030)
Table 32: Subgroups-Specific Diagnosed Prevalent Cases of DME in France (2018–2030)
Table 33: Treated Cases of DME in France (2018–2030)
Table 34: Total Prevalent Cases of DME in Italy (2018–2030)
Table 35: Total Diagnosed Prevalent Cases of DME in Italy (2018–2030)
Table 36: Age-specific Diagnosed Prevalent Cases of DME in Italy (2018–2030)
Table 37: Subgroups-Specific Diagnosed Prevalent Cases of DME in Italy (2018–2030)
Table 38: Treated Cases of DME in Italy (2018–2030)
Table 39: Total Prevalent Cases of DME in Spain (2018–2030)
Table 40: Total Diagnosed Prevalent Cases of DME in Spain (2018–2030)
Table 41: Gender-specific Diagnosed Prevalent Cases of DME in Spain (2018–2030)
Table 42: Age-specific Diagnosed Prevalent Cases of DME in Spain (2018–2030)
Table 43: Subgroups-Specific Diagnosed Prevalent Cases of DME in Spain (2018–2030)
Table 44: Treated Cases of DME in Spain (2018–2030)
Table 45: Total Prevalent Cases of DME in the United Kingdom (2018–2030)
Table 46: Total Diagnosed Prevalent Cases of DME in the United Kingdom (2018–2030)
Table 47: Gender-specific Diagnosed Prevalent Cases of DME in the United Kingdom (2018–2030)
Table 48: Age-specific Diagnosed Prevalent Cases of DME in the United Kingdom (2018–2030)
Table 49: Subgroups-Specific Diagnosed Prevalent Cases of DME in the United Kingdom (2018–2030)
Table 50: Treated Cases of DME in the United Kingdom (2018–2030)
Table 51: Total Prevalent Cases of DME in Japan (2018–2030)
Table 52: Total Diagnosed Prevalent Cases of DME in Japan (2018–2030)
Table 53: Gender-specific Diagnosed Prevalent Cases of DME in Japan (2018–2030)
Table 54: Age-specific Diagnosed Prevalent Cases of DME in Japan (2018–2030)
Table 55: Subgroups-Specific Diagnosed Prevalent Cases of DME in Japan (2018–2030)
Table 56: Treated Cases of DME in Japan (2018–2030)
Table 57: Ranibizumab, Clinical Trial Description, 2021
Table 58: Aflibercept, Clinical Trial Description, 2021
Table 59: Beovu (Brolucizumab), Clinical Trial Description, 2021
Table 60: Faricimab, Clinical Trial Description, 2021
Table 61: Patent Information
Table 62: KSI-301, Clinical Trial Description, 2021
Table 63: ADVM-022, Clinical Trial Description, 2021
Table 64: GB-102, Clinical Trial Description, 2021
Table 65: THR-149, Clinical Trial Description, 2021
Table 66: LKA651, Clinical Trial Description, 2021
Table 67: APX3330, Clinical Trial Description, 2021
Table 68: YD-312, Clinical Trial Description, 2021
Table 69: Abicipar, Clinical Trial Description, 2021
Table 70: Luminate (ALG-1001, Risuteganib), Clinical Trial Description, 2021
Table 71: Xipere, Clinical Trial Description, 2021
Table 72: KVD001, Clinical Trial Description, 2021
Table 73: 7MM Market Size of DME in USD Million (2018–2030)
Table 74: 7MM Market Size of DME by Treatment Options in USD Million (2018–2030)
Table 75: The United States Market Size of DME in USD Million (2018–2030)
Table 76: The United States Market Size of DME by Treatment Options in USD Million (2018–2030)
Table 77: Germany Market Size of DME in USD Million (2018–2030)
Table 78: Germany Market Size of DME by Treatment Options in USD Million (2018–2030)
Table 79: France Market Size of DME in USD Million (2018–2030)
Table 80: France Market Size of DME by Treatment Options in USD Million (2018–2030)
Table 81: Italy Market Size of DME in USD Million (2018–2030)
Table 82: Italy Market Size of DME by Treatment Options in USD Million (2018–2030)
Table 83: Spain Market Size of DME in USD Million (2018–2030)
Table 84: Spain Market Size of DME by Treatment Options in USD Million (2018–2030)
Table 85: The United Kingdom Market Size of DME in USD Million (2018–2030)
Table 86: The United Kingdom Market Size of DME by Treatment Options in USD Million (2018–2030)
Table 87: Japan Market Size of DME in USD Million (2018–2030)
Table 88: Japan Market Size of DME by Treatment Options in USD Million (2018–2030)
Table 89: DME Treatment cost
Table 90: NICE Recommendations
List of Figures
Figure 1: Total Prevalent Cases of DME in the 7MM (2018–2030)
Figure 2: Total Diagnosed Prevalent cases of DME in the 7MM (2018–2030)
Figure 3: Gender-specific Diagnosed Prevalent Cases of DME in the 7MM (2018–2030)
Figure 4: Age-specific Diagnosed Prevalent Cases of DME in the 7MM (2018–2030)
Figure 5: Subgroups-Specific Diagnosed Prevalent Cases of DME in the 7MM (2018–2030)
Figure 6: Treated cases of DME in the 7MM (2018–2030)
Figure 7: Total Prevalent Cases of DME in the United States (2018–2030)
Figure 8: Total Diagnosed Prevalent cases of DME in the United States (2018–2030)
Figure 9: Gender-specific Diagnosed Prevalent Cases of DME in the United States (2018–2030)
Figure 10: Age-specific Diagnosed Prevalent Cases of DME in the United States (2018–2030)
Figure 11: Subgroups-Specific Diagnosed Prevalent Cases of DME in the United States (2018–2030)
Figure 12: Treated cases of DME in the United States (2018–2030)
Figure 13: Total Prevalent Cases of DME in Germany (2018–2030)
Figure 14: Total Diagnosed Prevalent cases of DME in Germany (2018–2030)
Figure 15: Gender-specific Diagnosed Prevalent Cases of DME in Germany (2018–2030)
Figure 16: Age-specific Diagnosed Prevalent Cases of DME in Germany (2018–2030)
Figure 17: Subgroups-Specific Diagnosed Prevalent Cases of DME in Germany (2018–2030)
Figure 18: Treated cases of DME in Germany (2018–2030)
Figure 19: Total Prevalent Cases of DME in France (2018–2030)
Figure 20: Total Diagnosed Prevalent cases of DME in France (2018–2030)
Figure 21: ender-specific Diagnosed Prevalent Cases of DME in France (2018–2030)
Figure 22: Gender-specific Diagnosed Prevalent Cases of DME in France (2018–2030)
Figure 23: Age-specific Diagnosed Prevalent Cases of DME in France (2018–2030)
Figure 24: Subgroups-Specific Diagnosed Prevalent Cases of DME in France (2018–2030)
Figure 25: Treated cases of DME in France (2018–2030)
Figure 26: Total Prevalent Cases of DME in Italy (2018–2030)
Figure 27: Total Diagnosed Prevalent cases of DME in Italy (2018–2030)
Figure 28: Gender-specific Diagnosed Prevalent Cases of DME in Italy (2018–2030)
Figure 29: Gender-specific Diagnosed Prevalent Cases of DME in Italy (2018–2030)
Figure 30: Age-specific Diagnosed Prevalent Cases of DME in Italy (2018–2030)
Figure 31: Subgroups-Specific Diagnosed Prevalent Cases of DME in Italy (2018–2030)
Figure 32: Treated cases of DME in Italy (2018–2030)
Figure 33: Total Prevalent Cases of DME in Spain (2018–2030)
Figure 34: Total Diagnosed Prevalent cases of DME in Spain (2018–2030)
Figure 35: Gender-specific Diagnosed Prevalent Cases of DME in Spain (2018–2030)
Figure 36: Age-specific Diagnosed Prevalent Cases of DME in Spain (2018–2030)
Figure 37: Subgroups-Specific Diagnosed Prevalent Cases of DME in Spain (2018–2030)
Figure 38: Treated cases of DME in Spain (2018–2030)
Figure 39: Total Prevalent Cases of DME in the United Kingdom (2018–2030)
Figure 40: Total Diagnosed Prevalent cases of DME in the United Kingdom (2018–2030)
Figure 41: Gender-specific Diagnosed Prevalent Cases of DME in the United Kingdom (2018–2030)
Figure 42: Age-specific Diagnosed Prevalent Cases of DME in the United Kingdom (2018–2030)
Figure 43: Subgroups-Specific Diagnosed Prevalent Cases of DME in the United Kingdom (2018–2030)
Figure 44: Total Prevalent Cases of DME in the United Kingdom (2018–2030)
Figure 45: Total Prevalent Cases of DME in Japan (2018–2030)
Figure 46: Total Diagnosed Prevalent cases of DME in Japan (2018–2030)
Figure 47: Gender-specific Diagnosed Prevalent Cases of DME in Japan (2018–2030)
Figure 48: Age-specific Diagnosed Prevalent Cases of DME in Japan (2018–2030)
Figure 49: Subgroups-Specific Diagnosed Prevalent Cases of DME in Japan (2018–2030)
Figure 50: Treated cases of DME in Japan (2018–2030)
Figure 51: Mechanism of action of GB-102
Figure 52: Mechanism of THR-149
Figure 53: Mechanism of action of Risuteganib
Figure 54: Market Size of DME in the 7MM, USD Million (2018–2030)
Figure 55: 7MM Market Size of DME by Treatment Options in USD Million (2018–2030)
Figure 56: Market Size of DME in the United States, USD Million (2018–2030)
Figure 57: The United States Market Size of DME by Treatment Options in USD Million (2018–2030)
Figure 58: Market Size of DME in Germany, USD Million (2018–2030)
Figure 59: Germany Market Size of DME by Treatment Options in USD Million (2018–2030)
Figure 60: Market Size of DME in France, USD Million (2018–2030)
Figure 61: France Market Size of DME by Treatment Options in USD Million (2018–2030)
Figure 62: Market Size of DME in Italy, USD Million (2018–2030)
Figure 63: Italy Market Size of DME by Treatment Options in USD Million (2018–2030)
Figure 64: Market Size of DME in Spain, USD Million (2018–2030)
Figure 65: Spain Market Size of DME by Treatment Options in USD Million (2018–2030)
Figure 66: Market Size of DME in the United Kingdom, USD Million (2018–2030)
Figure 67: The United Kingdom Market Size of DME by Treatment Options in USD Million (2018–2030)
Figure 68: Market Size of DME in Japan, USD Million (2018–2030)
Figure 69: Japan Market Size of DME by Treatment Options in USD Million (2018–2030)
• Adverum Biotechnologies
• Graybug Vision
• Roche
• Novartis
• KalVista Pharmaceuticals
• Ocuphire Pharma
• Oxurion
• YD Life Science
• Novartis
• Allergan (AbbVie)/Molecular Partners
• Allergo Opthalmics/ Bausch Health
• Kodiak Sciences
• Clearside Biomedical
